Treatment of plasminogen activator in ophthalmology

Treatment of plasminogen activator in ophthalmology - Treatment of t-PA in ophthalmology

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029838

Enrollment

Registered

2017-11-06

Start date

2017-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Submacular hemorrhage, Retinal vein occlusion, Fibrin formation due to postoperative inflammation

Interventions

Injecting tissue plasminogen activator(0.025mg/0.1ml)0.02-0.2ml into a subretinal cavity or a retinal vascular in vitreous surgery. Injecting tissue plasminogen activator(0.025mg/0.1ml)0.05-0.1ml int

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients who have submacular hemorrhage, RVO, fibrin formation due to postoperative inflammation (2)Patients who were sufficient explanatation about using t-PA, and could get informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients who are during lactation or pregnancy or expected pregnancy (2)Patients who have active eye/eyelid inflammation or disease or infection (3)Patients who have hemorrhagic diathesis (4)Patients who are judged to be inappropriate for this trial by the judgement of the doctor.

Design outcomes

Primary

Measure	Time frame
Adverse event	—

Secondary

Measure	Time frame
Visual acuity, Visual field, Retinal thickness, Intraocular pressure	—

Countries

Japan

Contacts

Public ContactToshinori Masaki

Kanazawa University Department of Ophthalmology

tmasaki@med.kanazawa-u.ac.jp0762652403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026